pyrazinamide has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we report a case of peritoneal tuberculosis which was successfully treated with a non-rifampin based regimen in tandem with ongoing administration of a tyrosine kinase inhibitor, dasatinib, for CML." | 1.42 | Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis. ( Adelakun, A; Bhatnagar, V; Chen, Q; Emadi, A; Farshidpour, M; Holtzman, N; Kendall, T; Stevenson, B, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatnagar, V | 1 |
| Adelakun, A | 1 |
| Kendall, T | 1 |
| Holtzman, N | 1 |
| Farshidpour, M | 1 |
| Stevenson, B | 1 |
| Chen, Q | 1 |
| Emadi, A | 1 |
1 other study available for pyrazinamide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis.
Topics: Adult; Antitubercular Agents; Dasatinib; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Le | 2015 |